Asia Pacific Hemoglobinopathies Market Report and Forecast 2025-2034

Asia Pacific Hemoglobinopathies Market Outlook

The global hemoglobinopathies market size was valued at USD 6.9 billion in 2024, with Asia Pacific holding a significant market share. The market is driven by the rising prevalence of thalassemia and sickle cell anemia. It is expected to grow at a CAGR of 9.7% during the forecast period of 2025-2034, with the values likely to attain USD 15.9 billion by 2034.

Key Takeaways

• Thalassemia is considered the most common hereditary hemoglobinopathy affecting 4.4 of every 10,000 live births . It is reported to be highly prevalent in Southeast Asia and southern China. The rising burden of these genetic blood disorders is expected to drive market demand.

• One of the major Asia Pacific hemoglobinopathies market trends is the growing emphasis on the development of advanced hemoglobinopathies therapies that can eliminate the need for blood transfusions. In January 2024, CorrectSequence Therapeutics in collaboration with Guangxi Medical University, announced that they had clinically cured a thalassemia patient using a genetic base-editing technology called CS-101.

• The National Sickle Cell Anaemia Elimination Mission was launched by the Indian government in July 2023 to facilitate screening, prevention, and management of sickle cell anemia. Such initiatives are likely to enhance the detection and management of hemoglobinopathies, which is anticipated to boost the market share.

Asia Pacific Hemoglobinopathies Market Analysis

Hemoglobinopathies are a group of inherited blood disorders that cause abnormalities in the structure or production of hemoglobin. These disorders can result in severe health issues such as anemia, tissue damage, and organ dysfunction. Common hemoglobinopathies include sickle cell disease and thalassemia. The rising advancements in drug development and gene therapy coupled with the increased availability and adoption of advanced treatments are significantly contributing to the Asia Pacific hemoglobinopathies market growth.

Recent data suggests that around 300,000 to 500,000 children are born with severe hemoglobinopathies, out of which nearly 80% of the cases occur in developing countries. Thalassemia is considered the most common hereditary hemoglobinopathy, affecting 4.4 of every 10,000 live births . It is reported to be prevalent in Southeast Asia and southern China. The rising burden of these genetic blood disorders necessitates the need for advanced diagnostics and treatments, which are likely to augment the Asia Pacific hemoglobinopathies market demand in the forecast period.

One of the major market trends is the growing emphasis on the development of innovative hemoglobinopathies therapies. In January 2024, a China-based gene-editing pharmaceutical company CorrectSequence Therapeutics in collaboration with Guangxi Medical University, announced that they had clinically cured an adolescent patient with transfusion-dependent beta-thalassemia using a genetic base-editing one-time treatment called CS-101. The rising introduction of such advanced therapies in clinical settings that can eliminate the need for blood transfusions in such conditions is poised to boost the Asia Pacific hemoglobinopathies market share.

The market is also influenced by increased government initiatives such as screening programs and awareness campaigns to educate the public regarding the management and associated risks with the disorders. For instance, in July 2023, the Indian government initiated the National Sickle Cell Anaemia Elimination Mission, intended to facilitate screening, prevention, and management of sickle cell anemia in all tribal and other highly prevalent regions of India. Under the program, over 1 crore (10 million) people were screened for sickle cell anemia within 1 year. Such initiatives are likely to enhance the detection and management of hemoglobinopathies, which is anticipated to propel the market growth in the coming years.

Asia Pacific Hemoglobinopathies Market Segmentation

The report a detailed analysis of the market based on the following segments:

Asia Pacific Hemoglobinopathies Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Bio-Rad Laboratories, Inc.

• Bristol-Myers Squibb Company

• Novartis AG

• Pfizer Limited

• Merck KGaA

• Alnylam Pharmaceuticals, Inc.

• Sanofi

• Neusoft Corporation

• Emmaus UK

• Biogen

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report